Literature DB >> 8420607

Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.

A W Hsing1, G W Comstock.   

Abstract

A population-based nested case-control study was conducted to determine the relation of prediagnostic serum levels of testosterone, dihydrotestosterone, prolactin, follicle-stimulating hormone, luteinizing hormone, estrone, and estradiol to the risk of subsequent prostate cancer. Serum specimens of study subjects were available from a blood collection campaign in Washington County, Maryland, in 1974. Serum hormone levels of 98 histologically confirmed prostate cancer cases diagnosed in the subsequent 13 years were compared to those of 98 controls who were individually matched to cases on the basis of age (within weeks), sex, and race. There were no significant differences in levels of these hormones between cases and controls, although elevated levels of luteinizing hormone and of testosterone:dihydrotestosterone ratios were associated with mild increased risks of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420607

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  22 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

2.  High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer.

Authors:  Zakaria Y Abd Elmageed; Krzysztof Moroz; Sudesh K Srivastav; Zhide Fang; Byron E Crawford; Krishnarao Moparty; Raju Thomas; Asim B Abdel-Mageed
Journal:  Carcinogenesis       Date:  2013-05-08       Impact factor: 4.944

Review 3.  Nutrition and prostate cancer.

Authors:  L N Kolonel
Journal:  Cancer Causes Control       Date:  1996-01       Impact factor: 2.506

Review 4.  Is race an independent prognostic factor for survival from prostate cancer?

Authors:  M Roach
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

5.  Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norwegian men.

Authors:  I Thune; E Lund
Journal:  Cancer Causes Control       Date:  1994-11       Impact factor: 2.506

6.  Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients.

Authors:  S O Asbell; K C Raimane; A T Montesano; K L Zeitzer; M D Asbell; S Vijayakumar
Journal:  J Natl Med Assoc       Date:  2000-09       Impact factor: 1.798

7.  Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2003

8.  Androgenetic alopecia at various ages and prostate cancer risk in an equal-access multiethnic case-control series of veterans.

Authors:  Jean-Alfred Thomas; Jodi A Antonelli; Lionel L Banez; Catherine Hoyo; Delores Grant; Wendy Demark-Wahnefried; Elizabeth A Platz; Leah Gerber; Kathryn Shuler; Enwono Eyoh; Elizabeth Calloway; Stephen J Freedland
Journal:  Cancer Causes Control       Date:  2013-03-26       Impact factor: 2.506

9.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

10.  Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations.

Authors:  K V Honn; A Aref; Y Q Chen; M L Cher; J D Crissman; J D Forman; X Gao; D Grignon; M Hussain; A T Porter; J E Pontes; I Powell; B Redman; W Sakr; R Severson; D G Tang; D P Wood
Journal:  Pathol Oncol Res       Date:  1996-03       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.